BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22002443)

  • 1. Point mutation instability (PIN) mutator phenotype as model for true back mutations seen in hereditary tyrosinemia type 1 - a hypothesis.
    van Dyk E; Pretorius PJ
    J Inherit Metab Dis; 2012 May; 35(3):407-11. PubMed ID: 22002443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.
    Aponte JL; Sega GA; Hauser LJ; Dhar MS; Withrow CM; Carpenter DA; Rinchik EM; Culiat CT; Johnson DK
    Proc Natl Acad Sci U S A; 2001 Jan; 98(2):641-5. PubMed ID: 11209059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Aspects of the FAH Mutations Involved in HT1 Disease.
    Morrow G; Angileri F; Tanguay RM
    Adv Exp Med Biol; 2017; 959():25-48. PubMed ID: 28755182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct sequencing of FAH gene in Pakistani tyrosinemia type 1 families reveals a novel mutation.
    Ijaz S; Zahoor MY; Imran M; Afzal S; Bhinder MA; Ullah I; Cheema HA; Ramzan K; Shehzad W
    J Pediatr Endocrinol Metab; 2016 Mar; 29(3):327-32. PubMed ID: 26565546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability.
    Jorquera R; Tanguay RM
    Hum Mol Genet; 2001 Aug; 10(17):1741-52. PubMed ID: 11532983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.
    Orejuela D; Jorquera R; Bergeron A; Finegold MJ; Tanguay RM
    J Hepatol; 2008 Feb; 48(2):308-17. PubMed ID: 18093685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired DNA repair and genomic stability in hereditary tyrosinemia type 1.
    van Dyk E; Pretorius PJ
    Gene; 2012 Mar; 495(1):56-61. PubMed ID: 22209984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional analysis of missense mutations in fumarylacetoacetate hydrolase, the gene deficient in hereditary tyrosinemia type 1.
    Bergeron A; D'Astous M; Timm DE; Tanguay RM
    J Biol Chem; 2001 May; 276(18):15225-31. PubMed ID: 11278491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia.
    Demers SI; Russo P; Lettre F; Tanguay RM
    Hum Pathol; 2003 Dec; 34(12):1313-20. PubMed ID: 14691918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compound mutations (R237X and L375P) in the fumarylacetoacetate hydrolase gene causing tyrosinemia type I in a Chinese patient.
    Cao YY; Zhang YL; DU J; Qu YJ; Zhong XM; Bai JL; Song F
    Chin Med J (Engl); 2012 Jun; 125(12):2132-6. PubMed ID: 22884142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of mutations causing hereditary tyrosinemia type I in patients of Middle Eastern origin.
    Imtiaz F; Rashed MS; Al-Mubarak B; Allam R; El-Karaksy H; Al-Hassnan Z; Al-Owain M; Al-Zaidan H; Rahbeeni Z; Qari A; Meyer BF; Al-Sayed M
    Mol Genet Metab; 2011 Dec; 104(4):688-90. PubMed ID: 21764616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment.
    Langlois C; Jorquera R; Orejuela D; Bergeron A; Finegold MJ; Rhead WJ; Tanguay RM
    Mol Genet Metab; 2008 Mar; 93(3):306-13. PubMed ID: 18023223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.
    Li L; Zhang Q; Yang H; Zou Q; Lai C; Jiang F; Zhao P; Luo Z; Yang J; Chen Q; Wang Y; Newsome PN; Frampton J; Maxwell PH; Li W; Chen S; Wang D; Siu TS; Tam S; Tse HF; Qin B; Bao X; Esteban MA; Lai L
    J Biol Chem; 2017 Mar; 292(11):4755-4763. PubMed ID: 28053091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype.
    Neuckermans J; Lequeue S; Claes P; Heymans A; Hughes JH; Colemonts-Vroninks H; Marcélis L; Casimir G; Goyens P; Martens GA; Gallagher JA; Vanhaecke T; Bou-Gharios G; De Kock J
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary tyrosinemia type I-associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate.
    Macias I; Laín A; Bernardo-Seisdedos G; Gil D; Gonzalez E; Falcon-Perez JM; Millet O
    J Biol Chem; 2019 Aug; 294(35):13051-13060. PubMed ID: 31300554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel homozygous mutation causing hereditary tyrosinemia type I in yakut patient in russia: case report.
    Maksimova NR; Gurinova EE; Sukhomyasova AL; Danilova AL; Kaimonov VS; Savvina MT; Yakovleva AE; Alekseeva EI
    Wiad Lek; 2016; 69(2 Pt 2):295-8. PubMed ID: 27487552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Targeting of Fumaryl Acetoacetate Hydrolase in Hereditary Tyrosinemia Type I.
    Gil-Martínez J; Macias I; Unione L; Bernardo-Seisdedos G; Lopitz-Otsoa F; Fernandez-Ramos D; Lain A; Sanz-Parra A; Mato JM; Millet O
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The compound heterozygous mutations of c.607G>a and c.657delC in the FAH gene are associated with renal damage with hereditary tyrosinemia type 1 (HT1).
    Chi H; Gan C; Jiang Y; Chen D; Qiu J; Yang Q; Chen Y; Wang M; Yang H; Jiang W; Li Q
    Mol Genet Genomic Med; 2023 Jan; 11(1):e2090. PubMed ID: 36369907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
    VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
    Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of three mutations in the fumarylacetoacetate hydrolase gene in a patient with atypical symptoms of hereditary tyrosinemia type I.
    Morrow G; Dreumont N; Bourrelle-Langlois M; Roy V; Tanguay RM
    Mol Genet Metab; 2019 May; 127(1):58-63. PubMed ID: 30954369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.